Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
4hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0626 ET – The Novo Nordisk Foundation is strongly interested in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback